May 29, 2024 · BC3195 is known as the only antibody drug conjugate (ADC) in clinical stage, targeting CDH3 with payload of monomethyl auristatin E (MMAE). Methods: A phase I, open-label, first in human study to evaluate the safety, tolerability, PK, and preliminary antitumor activity of BC3195 is being performed in subjects with advanced solid malignancies.

Sep 23, 2024 · BC3195 is currently the only ADC targeting CDH3(P-Cadherin) in clinical development globally. In preclinical studies, BC3195 binds to membrane CDH3 with strong affinity and is efficiently internalized.

Jul 1, 2021 · P-cadherin is expressed at high level in a variety of human malignancies and is targetable via an ADC approach. A, CDH3 expression in TPM reads across normal tissue (red) and cancer tissue (blue) samples. Black dashed lines represent median expression ± SD.

Apr 19, 2024 · To validate the suitability of the targets for a bispecific ADC approach, we first set out to evaluate the bulk mRNA levels of CDH3 (the gene encoding pCAD) and CDH17 in both human normal tissue and cancer samples using publicly available datasets from The Cancer Genome Atlas (TCGA)21 and Gene-Tissue-Expression (GTEX)22.

Sep 12, 2024 · BC3195 is currently the only ADC targeting CDH3/P-Cadherin in clinical development globally. In preclinical studies, BC3195 binds to membrane CDH3 with strong affinity and is efficiently internalized.

BC3195 is known as the only antibody drug conjugate (ADC) in clinical stage, targeting CDH3 with payload of monomethyl auristatin E (MMAE). Methods: A phase I, open-label, first in human study to evaluate the safety, toler-ability, PK, and preliminary antitumor activity of BC3195 is being performed in subjects with advanced solid malignancies.

BC3195 is known as the only ADC in clinical stage, targeting CDH3 with payload of MMAE. A phase I, open-label, first in human study to evaluate the safety, tolerability, PK, and preliminary antitumor activity of BC3195 is being performed in patients …

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the human tumor-associated antigen (TAA) cadherin-3 (CDH3; placental cadherin; P-cadherin), conjugated to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (VC) peptide linker, with ...

2024年9月14日，智康弘义在ESMO会议上公布了全球首款CDH3 ADC新药BC3195的一期临床最新数据。 截至2024年8月10日，共入组34例患者，0.3mg/kg、0.6mg/kg、1.2mg/kg、1.8mg/kg Q3W剂量组分别入组3例患者，2.4mg/kg Q3W剂量组入组21例患者，另有1例患者接受1.2mg/kg QW治疗。 安全性方面，1例患者出现3级咽炎，被认定为DLT。 常见副作用包括皮疹、口腔炎、肝功能异常等。 皮疹、口腔炎主要出现在第一个治疗cycle且可管理。 14（41.2%）例患者经 …

CDH3 expression is associated with cancer aggressiveness, invasiveness, and poor prognosis. BC3195 is the only known antibody drug conjugate (ADC) in clinical stage that targets CDH3 with a monomethyl auristatin E (MMAE) payload.